This might be the earliest critical signaling target of the PD-1-PD-L1 pathway in the context of cancer, because soluble factors produced by cancer cells can act systemically at early stages of the cancer immunity cycle, before local tumor growth and infiltration by immune cells that are subject to inhibitory signals in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.